Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
- Revenue in GBP (TTM)--
- Net income in GBP--
- Incorporated2021
- Employees24.00k
- LocationHaleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
- Phone+44 193 282 2000
- Websitehttps://www.haleon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka Holdings Co Ltd | 11.60bn | 2.15bn | 27.57bn | 35.34k | 12.56 | 1.96 | 10.17 | 2.38 | 842.65 | 842.65 | 4,540.85 | 5,413.66 | 0.64 | 2.11 | 4.86 | 68,439,860.00 | 12.01 | 5.91 | 15.12 | 7.27 | 71.72 | 69.18 | 18.76 | 9.89 | 1.65 | -- | 0.0695 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
| Teva Pharmaceutical Industries Ltd | 12.64bn | 1.03bn | 29.02bn | 31.17k | 28.06 | 4.94 | 16.47 | 2.30 | 3.75 | 3.75 | 46.02 | 21.26 | 0.431 | 2.64 | 5.10 | 1,710,631.00 | 3.50 | -1.47 | 5.25 | -2.08 | 52.72 | 50.58 | 8.13 | -4.04 | 0.8002 | 4.54 | 0.6799 | -- | 4.32 | 0.709 | 186.03 | -- | -2.82 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.72bn | 229.86m | 30.55bn | 2.50k | 140.03 | 52.74 | 112.88 | 11.23 | 2.25 | 2.25 | 27.82 | 5.96 | 0.8068 | 8.46 | 7.20 | 1,485,575.00 | 6.82 | -12.28 | 9.57 | -16.14 | 81.64 | 83.20 | 8.45 | -24.70 | 2.71 | 3.50 | 0.7737 | -- | 65.19 | 49.77 | 212.79 | -- | -3.56 | -- |
| Sun Pharmaceutical Industries Ltd | 4.60bn | 848.95m | 32.95bn | 43.00k | 38.85 | -- | 30.38 | 7.17 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | -100.00bn | -100.00bn | 36.45bn | 24.00k | -- | 2.31 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| CSL Ltd | 11.38bn | 2.20bn | 37.72bn | 32.07k | 17.22 | 2.66 | 12.42 | 3.32 | 8.71 | 8.71 | 45.14 | 56.34 | 0.4019 | 1.20 | 5.16 | 684,542.30 | 8.10 | 8.58 | 9.87 | 10.61 | 51.93 | 52.91 | 20.16 | 19.71 | 1.12 | 10.01 | 0.3494 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Zoetis Inc | 6.94bn | 1.96bn | 39.17bn | 14.50k | 21.03 | -- | 16.90 | 5.65 | 6.02 | 6.02 | 21.33 | -- | -- | -- | -- | 652,896.60 | -- | 16.21 | -- | 19.61 | 71.87 | 70.68 | 28.23 | 27.03 | -- | 20.95 | -- | 30.59 | 2.28 | 7.24 | 7.52 | 10.29 | 6.51 | 20.11 |
| Bayer AG | 39.88bn | -172.16m | 39.28bn | 88.50k | -- | 1.53 | 13.28 | 0.985 | -0.2015 | -0.2015 | 46.69 | 30.11 | 0.4344 | 1.58 | 4.52 | 494,165.80 | -0.1639 | -2.66 | -0.2205 | -3.61 | 56.35 | 57.98 | -0.3772 | -6.88 | 0.7096 | 2.33 | 0.5717 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.29bn | 791.96m | 39.39bn | 20.24k | 49.69 | 6.50 | -- | 11.99 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Takeda Pharmaceutical Co Ltd | 21.42bn | 541.78m | 42.85bn | 47.46k | 77.69 | 1.16 | 10.38 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 23 Sep 2025 | 359.60m | 4.04% |
| Dodge & Coxas of 30 Sep 2024 | 233.28m | 2.62% |
| The Vanguard Group, Inc.as of 01 Jan 2026 | 223.09m | 2.51% |
| BlackRock Fund Advisorsas of 06 Mar 2025 | 196.79m | 2.21% |
| BlackRock Investment Management (UK) Ltd.as of 01 Jan 2026 | 181.50m | 2.04% |
| MFS International (UK) Ltd.as of 01 Jan 2026 | 172.01m | 1.93% |
| Harding Loevner LPas of 01 Jan 2026 | 132.71m | 1.49% |
| Franklin Mutual Advisers LLCas of 01 Jan 2026 | 131.98m | 1.48% |
| Norges Bank Investment Managementas of 01 Jan 2026 | 129.69m | 1.46% |
| First Eagle Investment Management LLCas of 01 Jan 2026 | 127.54m | 1.43% |
